Kura Oncology, Inc. - 8-K Filing
Kura Oncology reported $5.8 million in net product revenue for KOMZIFTI™ (ziftomenib) during its first full quarter of commercialization ending March 31, 2026. The company also recorded collaboration revenue of $12.5 million and had a cash balance of $580.8 million as of that date. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $KURA